๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Call for risk/benefit study of gene therapy

โœ Scribed by Butler, Declan


Book ID
109790682
Publisher
Nature Publishing Group
Year
1994
Tongue
English
Weight
137 KB
Volume
372
Category
Article
ISSN
0028-0836

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Gene therapy strategies for hemophilia:
โœ Inge Petrus; Marinee Chuah; Thierry VandenDriessche ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 167 KB

## Abstract Hemophilia is an inherited bleeding disorder caused by a deficiency of functional clotting factors VIII or IX in the blood plasma. The drawbacks of the classical protein substitution therapy fueled interest in alternative treatments by gene therapy. Hemophilia has been recognized as an

Call for UK gene therapy
โœ Aldhous, Peter ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› Nature Publishing Group ๐ŸŒ English โš– 173 KB
Benefits and risks of combination therap
โœ Norah A. Terrault ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 102 KB

In successful antiviral therapy of hepatitis B, drug combinations, particularly combinations without cross-resistance, can delay or prevent the emergence of drug-resistant mutants. Because drug-resistant mutants are archived and may limit future therapeutic options, prevention is important for long-

Benefits and risks of interferon therapy
โœ Robert Perrillo ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 120 KB

Alpha interferon is the only licensed drug for hepatitis B with immunomodulatory as well as viral inhibitory properties. Potential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a finite and defined treatment course, and a higher likelihood for hepatitis B